CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-04 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale 10b5-1 | −12,604 | $16.85 | $212K | 296,791 |
| 2025-12-04 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −4,290 | 12,871 | ||
| 2025-12-04 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −4,157 | 62,360 | ||
| 2025-12-04 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise · Stock Option (right to buy) 10b5-1 | −4,157 | 112,247 | ||
| 2025-12-04 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −10,000 | $16.61 | $166K | 1,232,312 |
| 2025-12-03 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −27,212 | $18.61 | $506K | 1,242,312 |
| 2025-12-01 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −124,998 | $18.94 | $2.4M | 2,709,241 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise 10b5-1 | +11,980 | $6.55 | $78K | 281,323 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise 10b5-1 | +3,750 | $7.80 | $29K | 285,073 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise 10b5-1 | +94,384 | $12.14 | $1.1M | 379,457 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −162,820 | $19.50 | $3.2M | 216,637 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −11,980 | 0 | ||
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,750 | 0 | ||
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −94,384 | 8,581 | ||
| 2025-11-26 | ROBINS CHAD M CEO and Chairman | Sale 10b5-1 | −35,736 | $19.68 | $703K | 2,834,239 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +834 | $6.27 | $5K | 297,625 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +20,834 | $6.55 | $136K | 318,459 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +49,480 | $6.55 | $324K | 367,939 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +34,375 | $7.27 | $250K | 402,314 |
| 2025-11-21 | BENZENO SHARON Chief Commercial Ofc Imm Med | Option exercise 10b5-1 | +119,809 | $12.14 | $1.5M | 522,123 |
Page 24 of 120 · 2,386 trades